StockTipsArenaBeta

BUY Lupin Limited — Somil Mehta, Sharekhan

BUYLupin Limited
Lupin share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: 1–3 months21 Sept 2026via CNBC Awaaz.

Entry₹2,119.1Inferred
Target₹2,230
Total upside +5.23% (call closed)
Stop loss₹2,070-2.32% risk
Exit₹2,07028 Sept 2026, 12:09 pm
Stop-loss hit-2.32%
Follow Somil Mehta for new calls(38% target hit, 98 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 3 active Short-term calls on LUPINSee 84 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 28 Sept 2026
7 supporting3 opposing
Supports the BUY call (7)

Lupin Ltd has received tentative approval from the U.S. FDA for its Apixaban oral suspension, a generic version of a drug used to reduce the risk of stroke and blood clots.

BSE · Company Update·28 Sept · today

(opens in new tab)

5 other SEBI-registered advisors have active short-term BUY calls on this stock, with 4 issued in the last 14 days

Advisor consensus · same horizon·28 Sept · today

Lupin share price is currently 'overemphasizing' a risk while 'undermining' a positive, HSBC says

NewsCnbc-Tv18·22 Sept · 5d ago

(opens in new tab)

8 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·22 Sept · 6d ago

Lupin receives US FDA approval for Modafinil 100 mg, 200 mg tablets

NewsCnbc-Tv18·4 Sept · 3w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (3)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·27 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Somil Mehta, Sharekhan

Every call and its outcome